Welcome to our dedicated page for Twist Bioscience Corporation news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience Corporation stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience (NASDAQ: TWST) has expanded its DNA synthesis offering with the launch of Gene Fragments ranging from 1.8kb to 5.0kb in length. This industry-leading product is available through Twist's ecommerce platform, offering the same speed, quality, and affordability as shorter fragments. Key features include:
- Turnaround time starting at two business days
- Low error rate of 1:7,500 base pairs
- Customizable with no order limit
- Universally compatible with various downstream cloning methods
The expanded offering aims to serve researchers at all stages, from Makers to Buyers, and is particularly beneficial for RNA therapeutic screening applications. Twist's CEO, Emily M. Leproust, Ph.D., emphasized the company's goal to push the boundaries of DNA synthesis and meet diverse customer needs.
Twist Bioscience (NASDAQ: TWST) has announced the granting of 94,200 restricted stock units (RSUs) to 30 newly hired employees as an inducement for their employment. This action was taken under Twist's Inducement Equity Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a 48-month period, with 25% vesting on the one-year anniversary of the employee's start date and 1/16 vesting quarterly thereafter, contingent on continued employment. This plan is exclusively used for granting equity awards to new hires or those returning after a significant break in employment.
Twist Bioscience (Nasdaq: TWST) and bitBiome have announced a strategic collaboration, launching a joint Transaminase Enzyme Screening Kit. This kit contains 48 diverse transaminase enzymes for in-house screening and evaluation. The collaboration combines Twist's high-capacity DNA synthesis technology with bitBiome's proprietary database of over two billion microbe sequences.
The kit aims to provide labs and pharmaceutical companies with improved enzymes for biocatalysis, particularly for synthesizing active pharmaceutical ingredients (APIs). Transaminases are important in creating chiral amines, valuable building blocks for the pharmaceutical industry, offering a potential 'green alternative' to conventional synthesis methods.
This partnership leverages bitBiome's diverse sequence database and Twist's large-scale DNA synthesis capabilities to create innovative solutions for the biomanufacturing industry.
Twist Bioscience (NASDAQ: TWST) reported strong fiscal Q3 2024 results, with record revenue of $81.5 million, up 28% year-over-year. The company saw significant improvements in gross margin, reaching 43.3%, a 900 basis point increase from the previous year. Twist raised its FY 2024 revenue guidance to $310-$311 million and expects gross margin to be at the high end of the range at approximately 42%.
Key highlights include:
- SynBio revenue grew to $33.0 million
- NGS revenue increased to $43.4 million
- Biopharma revenue reached $5.1 million
- Shipped products to approximately 2,300 customers
- Launched new products including Multiplexed Gene Fragments and Express Antibodies
Despite the strong revenue growth, Twist reported a net loss of $85.6 million for the quarter, including a $45 million impairment related to Biopharma assets.
Twist Bioscience (NASDAQ: TWST) announced the first patient dosing in Pure Biologics' exploratory Phase 0 clinical study of PBA-0405, a fully human IgG1 antibody discovered using Twist's synthetic antibody phage display libraries. The study aims to evaluate the pharmacodynamic activity of PBA-0405 in solid tumors, including head and neck squamous cell carcinoma, certain soft-tissue sarcomas, and triple-negative breast cancer.
PBA-0405 targets ROR1, a tumor-associated antigen, and is designed to make tumors visible to the immune system and induce an immune response. This marks the first antibody identified using Twist Biopharma Solutions' Library of Libraries to be tested in patients, validating the potential of their synthetic antibody libraries for discovering novel drug candidates for hard-to-treat cancers.
Twist Bioscience (NASDAQ: TWST) announced it will release its fiscal 2024 third quarter financial results on Friday, August 2, 2024, before market opening. The company will host a conference call and live audio webcast at 8:00 a.m. ET to discuss the results and provide business updates. The press release with financial results will be accessible on Twist Bioscience's website under the Investor Relations section. Interested participants can register on the company's website to receive the necessary dial-in information for the call. A webcast replay will be available for two weeks.
Twist Bioscience (NASDAQ: TWST) has expanded its high-throughput antibody portfolio with the launch of the CHO Express Antibodies, complementing their existing HEK293 antibodies. This expansion aims to support biopharma companies by providing customizable, cost-effective, and scalable antibody production solutions. CHO cell lines are pivotal in biotherapeutic drug manufacturing, and Twist's new service can deliver sequence-perfect IgG antibodies in as few as 13 business days. The antibodies range from 15 μg to 3,000 μg and include detailed yield data for screening. This development improves the efficiency and reduces the costs associated with antibody discovery and production.
Twist Bioscience (NASDAQ: TWST) has introduced a synthetic RNA control for H5N1 Influenza A, a key contributor to Highly Pathogenic Avian Influenza (HPAI). The new control covers 99.9% of the hemagglutinin (HA) and neuraminidase (NA) genome regions, facilitating enhanced research without the need for live viruses.
CEO Emily M. Leproust highlighted the importance of providing innovative tools for global monitoring and vaccine development. The synthetic control allows work to be undertaken in BSL-1 labs, speeding up research while maintaining high biosecurity standards.
This launch is part of Twist's broader portfolio of synthetic viral controls and research tools, aimed at supporting next-generation sequencing (NGS) and polymerase chain reaction (PCR) assays. The company also offers products for other viral and respiratory diseases, including a comprehensive viral research panel for detecting H5N1 in wastewater.
Twist Bioscience (NASDAQ: TWST) has announced the discovery of TB206-001, a first-in-class antibody targeting the adenosine A2A receptor (A2AR), which could enhance cancer immunotherapy. The preclinical study, published in PLOS ONE, shows that TB206-001 has high affinity and tumor-suppressing activity, especially in colon tumor-bearing HuCD34-NCG mice, outperforming PD-1 inhibitors. The antibody targets GPCRs, common in immune cells and certain cancers, and works by blocking A2AR, thereby activating immune cells. Twist Bioscience is offering TB206-001 for out-licensing, indicating its potential for further clinical development.
Twist Bioscience (NASDAQ: TWST) announced its participation in the U.S. AI Safety Institute Consortium (AISIC), a group formed by the Department of Commerce’s National Institute of Standards and Technology (NIST). As part of the consortium, Twist Bioscience aims to advance the development and deployment of safe and trustworthy AI. The company emphasizes its commitment to biosecurity, leveraging its high-quality synthetic DNA and silicon platform to support the creation of interoperable safety standards. The consortium comprises over 200 member companies, including industry leaders, academia, government entities, and civil society organizations, all dedicated to ensuring the responsible growth of AI technologies.
FAQ
What is the current stock price of Twist Bioscience Corporation (TWST)?
What is the market cap of Twist Bioscience Corporation (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
